Astrana Health, Privia Miss Despite Revenue Growth; Omnicell Soars Post-Q3 Earnings

Healthcare technology-for-providers stocks posted mixed Q3 results ending December 31, 2025, with collective revenue beating estimates by 6.2% but forward guidance lagging by 0.7%. The group’s shares fell 4.9% on average post-earnings. Astrana Health (NASDAQ:ASTH) reported $956M in revenue—up 99.7% YoY—but missed EPS and full-year guidance, sending its stock down 6.4% to $22.35. Privia Health (NASDAQ:PRVA) beat revenue estimates by 16.6% with $580.4M (+32.5% YoY) yet also dropped 6.4% to $23.42. Evolent Health (NYSE:EVH) saw revenue fall 22.8% to $479.5M despite a guidance raise, triggering a 43.9% share plunge to $3.36. Only Omnicell (NASDAQ:OMCL) surged, jumping 63.9% to $48.47 after reporting $310.6M in revenue (+10% YoY) and strong EPS and guidance beats.